Theralase Technologies Inc
XTSX:TLT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.14
0.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Theralase Technologies Inc
Net Margin
Theralase Technologies Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | CA |
| Market Cap | 71.8m CAD |
| Net Margin |
-479%
|
| Country | US |
| Market Cap | 204.9B USD |
| Net Margin |
14%
|
| Country | US |
| Market Cap | 195.2B USD |
| Net Margin |
29%
|
| Country | US |
| Market Cap | 146.7B USD |
| Net Margin |
16%
|
| Country | US |
| Market Cap | 132.6B USD |
| Net Margin |
11%
|
| Country | IE |
| Market Cap | 110.6B USD |
| Net Margin |
12%
|
| Country | US |
| Market Cap | 64.7B USD |
| Net Margin |
9%
|
| Country | DE |
| Market Cap | 55.6B EUR |
| Net Margin |
8%
|
| Country | CN |
| Market Cap | 319.2B CNY |
| Net Margin |
34%
|
| Country | US |
| Market Cap | 41.6B USD |
| Net Margin |
74%
|
| Country | US |
| Market Cap | 37.7B USD |
| Net Margin |
9%
|
Theralase Technologies Inc
Glance View
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Theralase Technologies Inc's most recent financial statements, the company has Net Margin of -478.7%.
You don't have any saved screeners yet
